{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:06:52Z","timestamp":1790766412370,"version":"4.1.0"},"reference-count":37,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chungnam National University Hospital Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Metastasis is a major cause of death in renal cell carcinoma (RCC) patients; therefore, a better understanding of the metastatic process and the ability to predict metastasis in advance is important for treating patients with RCC. This study aimed to investigate whether histological subtypes of RCC and other factors, such as nuclear grade and sarcomatoid differentiation, could predict the probability and location of metastases in patients with RCC. Materials and Methods: Cases of clear-cell, papillary, chromophobe, and sarcomatoid RCC were retrieved and analyzed from the Surveillance, Epidemiology, and End Results databases. Results: When comparing the metastatic patterns among the three histologic subtypes, patients with clear-cell RCC were significantly more likely to have brain and lung metastases. Moreover, patients with papillary RCC were significantly less likely to develop bone metastases and more likely to develop lymph node metastases. Patients with chromophobe RCC are significantly more likely to develop liver metastases. As the nuclear grade increased, there was also a significantly increased tendency for clear-cell RCC to metastasize to the lungs. Patients with sarcomatoid RCC had a higher rate of metastasis, with a significantly higher probability of metastasis to the bone and lungs, than those with all three histological subtypes did. Conclusions: Histological subtype, nuclear grade, and sarcomatoid differentiation were significant predictors of metastasis in patients with RCC.<\/jats:p>","DOI":"10.3390\/medicina59101845","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T08:08:33Z","timestamp":1697530113000},"page":"1845","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Metastasis Pattern of Renal Cell Carcinoma Is Influenced by Histologic Subtype, Grade, and Sarcomatoid Differentiation"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5972-3516","authenticated-orcid":false,"given":"Hyung Kyu","family":"Park","sequence":"first","affiliation":[{"name":"Department of Pathology, Chungnam National University School of Medicine, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Makino, T., Kadomoto, S., Izumi, K., and Mizokami, A. (2022). Epidemiology and Prevention of Renal Cell Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14164059"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zhan, X., Chen, T., Liu, Y., Wan, H., Liu, X., Deng, X., Fu, B., and Xiong, J. (2023). Trends in Cause of Death among Patients with Renal Cell Carcinoma in the United States: A SEER-Based Study. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-15647-2"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10509","DOI":"10.1038\/s41598-019-46718-3","article-title":"Pan-Renal Cell Carcinoma Classification and Survival Prediction from Histopathology Images Using Deep Learning","volume":"9","author":"Tabibu","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Parosanu, A.I., Baston, C., Stanciu, I.M., Parlog, C.F., and Nitipir, C. (2023). Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers. Diagnostics, 13.","DOI":"10.3390\/diagnostics13142430"},{"key":"ref_7","unstructured":"(2022). Urinary and Male Genital Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Inamura, K. (2017). Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102195"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of Renal Cell Carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal Cell Carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2021869","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association with Survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17822","DOI":"10.1038\/s41598-021-97365-6","article-title":"The Prognosis and Clinicopathological Features of Different Distant Metastases Patterns in Renal Cell Carcinoma: Analysis Based on the SEER Database","volume":"11","author":"Wei","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00000478-200103000-00001","article-title":"Sarcomatoid Differentiation in Renal Cell Carcinoma: A Study of 101 Cases","volume":"25","author":"Moch","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1464-410X.2012.10934.x","article-title":"Unclassified Renal Cell Carcinoma: A Report of 56 Cases","volume":"110","author":"Kirkali","year":"2012","journal-title":"BJU Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/his.12803","article-title":"Gleason and Fuhrman No Longer Make the Grade","volume":"68","author":"Delahunt","year":"2016","journal-title":"Histopathology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","article-title":"The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters","volume":"37","author":"Delahunt","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5858\/arpa.2019-0551-RA","article-title":"Updates in Histologic Grading of Urologic Neoplasms","volume":"144","author":"Cornejo","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00345-018-2447-8","article-title":"WHO\/ISUP Classification, Grading and Pathological Staging of Renal Cell Carcinoma: Standards and Controversies","volume":"36","author":"Warren","year":"2018","journal-title":"World J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Li, L., Li, C.G., Almomani, S.N., Hossain, S.M., and Eccles, M.R. (2023). Co-Expression of Multiple PAX Genes in Renal Cell Carcinoma (RCC) and Correlation of High PAX Expression with Favorable Clinical Outcome in RCC Patients. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411432"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Apanovich, N., Matveev, A., Ivanova, N., Burdennyy, A., Apanovich, P., Pronina, I., Filippova, E., Kazubskaya, T., Loginov, V., and Braga, E. (2023). Prediction of Distant Metastases in Patients with Kidney Cancer Based on Gene Expression and Methylation Analysis. Diagnostics, 13.","DOI":"10.3390\/diagnostics13132289"},{"key":"ref_21","unstructured":"(2023, August 09). Surveillance, Epidemiology, and End Results Program Cancer Stat Facts: Kidney and Renal Pelvis Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.3390\/curroncol29080429","article-title":"Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma","volume":"29","author":"Cardenas","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nze, C., Msaouel, P., Derbala, M.H., Stephen, B., Abonofal, A., Meric-Bernstam, F., Tannir, N.M., and Naing, A. (2023). A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15153806"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Studentova, H., Spisarova, M., Kopova, A., Zemankova, A., Melichar, B., and Student, V. (2023). The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15153855"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Xu, S., Hu, X., Chong, Y., and Zhu, G. (2023). Investigating the Role of FoxP3 in Renal Cell Carcinoma Metastasis with BAP1 or SEDT2 Mutation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512301"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3346\/jkms.2023.38.e85","article-title":"Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs","volume":"38","author":"Park","year":"2023","journal-title":"J. Korean Med. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8794","DOI":"10.3390\/curroncol29110691","article-title":"Patterns of Extrathoracic Metastasis in Lung Cancer Patients","volume":"29","author":"Park","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.3390\/curroncol29100587","article-title":"Neuroendocrine Carcinomas of the Uterine Cervix, Endometrium, and Ovary Show Higher Tendencies for Bone, Brain, and Liver Organotrophic Metastases","volume":"29","author":"Park","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_29","unstructured":"Surveillance Research Program, National Cancer Institute (2023, July 23). SEER*Stat Software, Available online: www.seer.cancer.gov\/seerstat."},{"key":"ref_30","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (2023, July 23). SEER*Stat Database: Incidence\u2014SEER Research Data, 17 Registries, Nov 2022 Sub (2000\u20132020)\u2014Linked To County Attributes\u2014Time Dependent (1990\u20132021) Income\/Rurality, 1969\u20132021 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Released April 2023, Based on the November 2022 Submission, Available online: www.seer.cancer.gov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.3390\/curroncol29080433","article-title":"The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature","volume":"29","author":"Studentova","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/curroncol30010070","article-title":"Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature","volume":"30","author":"John","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00000478-198210000-00007","article-title":"Prognostic Significance of Morphologic Parameters in Renal Cell Carcinoma","volume":"6","author":"Fuhrman","year":"1982","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1084\/jem.20181617","article-title":"Kidney Cancer: The next Decade","volume":"215","author":"Turajlic","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.urolonc.2015.12.013","article-title":"Are Primary Renal Cell Carcinoma and Metastases of Renal Cell Carcinoma the Same Cancer?","volume":"34","author":"Stec","year":"2016","journal-title":"Urol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102528","DOI":"10.1016\/j.ctrv.2023.102528","article-title":"Post Nephrectomy Management of Localized Renal Cell Carcinoma. From Risk Stratification to Therapeutic Evidence in an Evolving Clinical Scenario","volume":"115","author":"Ciccarese","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/14737140.2021.1976147","article-title":"2021 ASCO Genitourinary Cancers Symposium: A Focus on Renal Cell Carcinoma","volume":"21","author":"Iacovelli","year":"2021","journal-title":"Expert Rev. Anticancer Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/10\/1845\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:08:17Z","timestamp":1760130497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/10\/1845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["medicina59101845"],"URL":"https:\/\/doi.org\/10.3390\/medicina59101845","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]}}}